
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences is expected to see an increase in royalty fees and other revenues due to the company's unique technologies and promising pipeline. Additionally, the company's personalized cancer vaccine candidate, IFx-2.0, has the potential to overcome primary resistance to checkpoint inhibitors, making it a highly sought after treatment in the immuno-oncology market. The company's strong financial performance in the form of increasing revenues and zero selling and marketing expenses also suggest positive growth potential.
Bears say
TuHURA Biosciences is expected to face significant risks due to its high reliance on the success of its personalized cancer vaccine candidate IFx-2.0, which has a low probability of approval. In addition, the company's anti-Vista mAb in AML has an even lower chance of approval, reducing the overall potential market value for the company. These risks, combined with potential delays and competition in the market, raise concerns about the long-term viability and success of TuHURA Biosciences as a profitable company.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares